Comparison of promestriene with vaginal fractional CO2 laser and radiofrequency treatments of genitourinary syndrome of menopause

Author(s)

Seganfredo, Isadora B. ; Bianchi, Cristina ; Tacla, Maricy ; Chedraui, Peter ; Haddad, Jorge M. ; Simoes, Ricardo ; Baracat, Edmund C. ; Soares Jr, Jose M.

• Document type: Journal article
• Source: MATURITAS; v. 186, p. 8-pg., 2024-06-12.

Abstract

Objective: To compare the effects of fractional CO2 laser and microablative fractional radiofrequency treatment with promestriene topical estrogen on sexual function and genitourinary syndrome of menopause symptoms. Methods: This was a prospective randomized open -label clinical trial conducted with 62 postmenopausal women assigned to three intervention groups: a) topical promestriene for 90 days ( n = 17); b) fractional CO2 laser treatment ( n = 24); and c) microablative fractional radiofrequency treatment ( n = 21). Each of the latter two groups underwent three treatment sessions at 4-week intervals. At baseline and at the end of the study, all participants had a gynecological examination that included vaginal pH measurement, and the completion of the Vaginal Symptom Score, the Vaginal Health Index, and the Female Sexual Function Index. For the energy treatment groups, adverse effects were evaluated after each session. Group homogeneity was assessed at baseline, and results were evaluated over time (from baseline to the end of treatment) and between groups over time. Results: All baseline parameters were similar among studied groups. At the end of the study, all 3 treatments had produced similar effects: a reduction of vaginal pH, and an improvement of vulvovaginal symptoms (Vaginal Symptom Score and Vaginal Health Index scores) as well as sexual function (higher total Female Sexual Function Index scores, and in the desire, arousal, lubrication and pain domain scores), with no differences observed between groups. Side-effects were slight for both energy treatment groups, mainly represented by vaginal discharge. Conclusion: The present study suggests that the two energy treatments were efficient along with promestriene at improving postmenopausal genitourinary and sexuality symptoms. Clinical trial identification number NCT04717245. (AU)

• FAPESP's process: 18/24224-9 - Extra reproductive effects of melatonin on the genital system and breast
• Grantee: José Maria Soares Junior
• Support Opportunities: Research Projects - Thematic Grants